For Debate: Preventing atherosclerotic events with aspirin
- 12 January 2002
- Vol. 324 (7329), 103-105
- https://doi.org/10.1136/bmj.324.7329.103
Abstract
No abstract availableKeywords
This publication has 14 references indexed in Scilit:
- Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patientsBMJ, 2002
- Does aspirin attenuate the effect of angiotensin-converting enzyme inhibitors in hypertension or heart failure?Current Opinion in Nephrology and Hypertension, 2001
- Prevention of pulmonary embolism and deep vein thrombosis with low dose aspirin: Pulmonary Embolism Prevention (PEP) trial.2000
- Peptic ulcer bleeding: accessory risk factors and interactions with non-steroidal anti-inflammatory drugsGut, 2000
- Anticoagulant and antiplatelet therapy in heart failureCurrent Opinion in Cardiology, 1997
- Is aspirin safe for patients with heart failure?Heart, 1995
- Collaborative overview of randomised trials of antiplatelet therapy--I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Antiplatelet Trialists' Collaboration.1994
- The German-Austrian aspirin trial: a comparison of acetylsalicylic acid, placebo and phenprocoumon in secondary prevention of myocardial infarction. On behalf of the German-Austrian Study Group.1980
- The aspirin myocardial infarction study: final results. The Aspirin Myocardial Infarction Study research group.1980
- Persantine and aspirin in coronary heart disease. The Persantine-Aspirin Reinfarction Study Research Group.Circulation, 1980